Company intelligence / Profile preview

Aelis Farma

Bordeaux, Nouvelle-Aquitaine, France

Ownership: Public · AELIS
Employees: ~25
Development stage: Other

Overview

In 2024–2025, Aelis Farma reported positive results from a Phase 2b trial for AEF0117 in cannabis use disorder and a Phase 1/2 study for AEF0217 in cognitive deficits associated with Down syndrome. Both studies confirmed safety and pharmacological activity of their novel CB1–SSi class. The company has expanded its proprietary platform to identify additional candidates targeting brain and peripheral diseases involving the CB1 receptor.

Therapeutic areas: PsychiatryNeurologyMetabolic Disorders
Modalities: Small molecules (Signaling Specific inhibitors of the CB1 receptor, or CB1-SSi)
Industry: Biotech

Drug pipeline

3 assets

aef0117

2 more assets in the full pipeline.

Request access →

Partnerships

Indivior PLC holds a license option agreement for development/commercialization rights to AEF0117 for cannabis use disorders

Financials

Market cap: $52.2B

Beyond the preview

Go deeper on Aelis Farma.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Aelis Farma.

Explore the full profile